OTCMKTS:FSNUY Fresenius SE & Co. (FSNUY) Stock Price, News & Analysis $10.40 -0.24 (-2.26%) As of 06/1/2026 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Fresenius SE & Co. Stock (OTCMKTS:FSNUY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fresenius SE & Co. alerts:Sign Up Key Stats Today's Range$10.33▼$10.4850-Day Range$10.40▼$13.2552-Week Range$10.33▼$33.93Volume334,266 shsAverage Volume183,994 shsMarket Capitalization$23.43 billionP/E Ratio13.87Dividend Yield1.92%Price TargetN/AConsensus RatingBuy Company Overview Fresenius SE & Co. KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co. brings together a portfolio of specialized healthcare businesses under one corporate umbrella. The company operates through four main business segments. Fresenius Medical Care is the largest provider of renal care products and services, including dialysis machines, disposables and clinic operations. Fresenius Kabi offers a broad range of lifesaving medicines, infusion therapies, clinical nutrition and medical devices for intravenous drug delivery. Fresenius Helios manages a network of acute care hospitals and outpatient facilities across Europe, while Fresenius Vamed specializes in planning, construction and management of healthcare projects and facilities, supporting clients from conception through operation. Fresenius serves patients and healthcare providers in more than 100 countries, with production sites, research centers and clinical operations spanning Europe, North America, Asia-Pacific and Latin America. The company emphasizes continuous innovation, investing in research and development to enhance patient outcomes and streamline care delivery. Under the leadership of Chief Executive Officer Dr. Stephan Sturm, Fresenius pursues a strategy of geographic expansion and portfolio optimization to address evolving global healthcare needs.AI Generated. May Contain Errors. Read More Fresenius SE & Co. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreFSNUY MarketRank™: Fresenius SE & Co. scored higher than 72% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingBuy Consensus RatingFresenius SE & Co. has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFresenius SE & Co. has only been the subject of 1 research reports in the past 90 days.Read more about Fresenius SE & Co.'s stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.57% Earnings GrowthEarnings for Fresenius SE & Co. are expected to grow by 8.57% in the coming year, from $1.05 to $1.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fresenius SE & Co. is 13.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Fresenius SE & Co. is 13.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.07.Price to Book Value per Share RatioFresenius SE & Co. has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Fresenius SE & Co.'s valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Fresenius SE & Co. has been sold short.Short Interest Ratio / Days to CoverFresenius SE & Co. has a short interest ratio ("days to cover") of 0.15, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fresenius SE & Co. has recently decreased by 65.76%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldFresenius SE & Co. pays a meaningful dividend of 1.89%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthFresenius SE & Co. does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Fresenius SE & Co. is 26.67%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Fresenius SE & Co. will have a dividend payout ratio of 17.54% next year. This indicates that Fresenius SE & Co. will be able to sustain or increase its dividend.Read more about Fresenius SE & Co.'s dividend. News and Social Media1.7 / 5News SentimentN/A News SentimentFresenius SE & Co. has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Fresenius SE & Co. this week, compared to 1 article on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Fresenius SE & Co. insiders have not sold or bought any company stock.Percentage Held by InstitutionsFresenius SE & Co. has minimal institutional ownership at this time.Read more about Fresenius SE & Co.'s insider trading history. Receive FSNUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fresenius SE & Co. and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FSNUY Stock News HeadlinesFresenius SE & Co. (OTCMKTS:FSNUY) & Ceres Ventures (OTCMKTS:CEVE) Financial ComparisonMay 26, 2026 | americanbankingnews.comFresenius SE & Co. (OTCMKTS:FSNUY) Sets New 12-Month Low - Should You Sell?May 23, 2026 | americanbankingnews.comElon Now Pays 15X More Than Your BankElon Musk's new bank is offering 6% interest per year - that's 15 times the national average of 0.4% that most Americans earn sitting in traditional accounts. Built from a project 27 years in the making, this financial platform is challenging the way America's biggest banks operate. Luke Lango is breaking down exactly what this means for your money.June 2 at 1:00 AM | InvestorPlace (Ad)Assessing Fresenius SE KGaA (XTRA:FRE) Valuation After Recent Earnings And Shareholder ReturnsMarch 1, 2026 | finance.yahoo.comFresenius SE Earnings Call Highlights Growth MomentumFebruary 28, 2026 | tipranks.comFresenius SE & Co. KGaA (FSNUY) Q4 2025 Earnings Call TranscriptFebruary 25, 2026 | seekingalpha.comGermany's Fresenius beats revenue expectations in fourth quarterFebruary 25, 2026 | msn.comFresenius SE & Co. KGaA (FSNUY) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14, 2026 | seekingalpha.comSee More Headlines FSNUY Stock Analysis - Frequently Asked Questions How have FSNUY shares performed this year? Fresenius SE & Co.'s stock was trading at $14.33 on January 1st, 2026. Since then, FSNUY shares have decreased by 27.4% and is now trading at $10.40. How were Fresenius SE & Co.'s earnings last quarter? Fresenius SE & Co. (OTCMKTS:FSNUY) announced its earnings results on Wednesday, May, 6th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by $0.01. The firm earned $6.75 billion during the quarter, compared to analyst estimates of $6.79 billion. Fresenius SE & Co. had a trailing twelve-month return on equity of 10.29% and a net margin of 6.55%. How do I buy shares of Fresenius SE & Co.? Shares of FSNUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/06/2026Today6/02/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryMedical Equipment Current SymbolOTCMKTS:FSNUY CIK904868 Webwww.fresenius.com Phone(496) 172-6080FaxN/AEmployees178,394Year Founded1912Profitability EPS (Trailing Twelve Months)$0.75 Trailing P/E Ratio13.87 Forward P/E Ratio9.90 P/E GrowthN/ANet Income$1.43 billion Net Margins6.55% Pretax Margin9.57% Return on Equity10.29% Return on Assets4.77% Debt Debt-to-Equity Ratio0.47 Current Ratio1.32 Quick Ratio1.00 Sales & Book Value Annual Sales$25.87 billion Price / Sales0.91 Cash Flow$1.53 per share Price / Cash Flow6.80 Book Value$9.93 per share Price / Book1.05Miscellaneous Outstanding Shares2,252,949,000Free FloatN/AMarket Cap$23.43 billion OptionableNot Optionable Beta0.68 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (OTCMKTS:FSNUY) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredThe Rare Earth Shift Few Saw ComingRare earth elements sit inside modern defense systems, high-performance magnets, and advanced electronics - ye...i2i Marketing Group, LLC | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredGold hit $4,500 - but these miners haven't caught up yet$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayOctober 14th, 2025, CNBC quietly published an interview with BlackRock's CEO, who went on live television and ...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fresenius SE & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fresenius SE & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FSNUY Stock Alerts